Copyright Reports & Markets. All rights reserved.

USA Oncology Biosimilars Market Report 2019

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Oncology Biosimilars Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 G-CSF Market Performance (Volume)
      • 2.1.2 Hematopoietic Agents Market Performance (Volume)
      • 2.1.3 Monoclonal Antibodies Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.2.1 G-CSF Market Performance (Value)
      • 2.2.2 Hematopoietic Agents Market Performance (Value)
      • 2.2.3 Monoclonal Antibodies Market Performance (Value)

    3 Market Assessment by Application

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Retail Pharmacies Market Performance (Volume)
      • 3.1.2 Hospital Pharmacies Market Performance (Volume)
      • 3.1.3 Online Pharmacies Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Celltrion Inc.
      • 4.1.1 Celltrion Inc. Profiles
      • 4.1.2 Celltrion Inc. Product Information
      • 4.1.3 Celltrion Inc. Oncology Biosimilars Business Performance
      • 4.1.4 Celltrion Inc. Oncology Biosimilars Business Development and Market Status
    • 4.2 Pfizer Inc.
      • 4.2.1 Pfizer Inc. Profiles
      • 4.2.2 Pfizer Inc. Product Information
      • 4.2.3 Pfizer Inc. Oncology Biosimilars Business Performance
      • 4.2.4 Pfizer Inc. Oncology Biosimilars Business Development and Market Status
    • 4.3 Biocon
      • 4.3.1 Biocon Profiles
      • 4.3.2 Biocon Product Information
      • 4.3.3 Biocon Oncology Biosimilars Business Performance
      • 4.3.4 Biocon Oncology Biosimilars Business Development and Market Status
    • 4.4 BIOCAD
      • 4.4.1 BIOCAD Profiles
      • 4.4.2 BIOCAD Product Information
      • 4.4.3 BIOCAD Oncology Biosimilars Business Performance
      • 4.4.4 BIOCAD Oncology Biosimilars Business Development and Market Status
    • 4.5 Apotex Inc.
      • 4.5.1 Apotex Inc. Profiles
      • 4.5.2 Apotex Inc. Product Information
      • 4.5.3 Apotex Inc. Oncology Biosimilars Business Performance
      • 4.5.4 Apotex Inc. Oncology Biosimilars Business Development and Market Status
    • 4.6 Dr. Reddy's Laboratories Ltd.
      • 4.6.1 Dr. Reddy's Laboratories Ltd. Profiles
      • 4.6.2 Dr. Reddy's Laboratories Ltd. Product Information
      • 4.6.3 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Performance
      • 4.6.4 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Development and Market Status
    • 4.7 Sandoz International GmbH
      • 4.7.1 Sandoz International GmbH Profiles
      • 4.7.2 Sandoz International GmbH Product Information
      • 4.7.3 Sandoz International GmbH Oncology Biosimilars Business Performance
      • 4.7.4 Sandoz International GmbH Oncology Biosimilars Business Development and Market Status
    • 4.8 Intas Pharmaceuticals Ltd.
      • 4.8.1 Intas Pharmaceuticals Ltd. Profiles
      • 4.8.2 Intas Pharmaceuticals Ltd. Product Information
      • 4.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Performance
      • 4.8.4 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Development and Market Status
    • 4.9 STADA Arzneimittel AG
      • 4.9.1 STADA Arzneimittel AG Profiles
      • 4.9.2 STADA Arzneimittel AG Product Information
      • 4.9.3 STADA Arzneimittel AG Oncology Biosimilars Business Performance
      • 4.9.4 STADA Arzneimittel AG Oncology Biosimilars Business Development and Market Status
    • 4.10 Teva Pharmaceutical Industries Ltd.
      • 4.10.1 Teva Pharmaceutical Industries Ltd. Profiles
      • 4.10.2 Teva Pharmaceutical Industries Ltd. Product Information
      • 4.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Performance
      • 4.10.4 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 USA Oncology Biosimilars Sales (K Units) and Market Share by Manufacturers (2014-2020)
    • 5.2 USA Oncology Biosimilars Revenue (M USD) and Market Share by Manufacturers (2014-2020)
    • 5.3 USA Oncology Biosimilars Price (USD/Unit) of Manufacturers (2014-2020)
    • 5.4 USA Oncology Biosimilars Gross Margin of Manufacturers (2014-2020)
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Northeast Market Performance for Manufacturers
      • 6.1.1 Northeast Oncology Biosimilars Sales (K Units) and Share of Manufacturers (2014-2020)
      • 6.1.2 Northeast Oncology Biosimilars Revenue (M USD) and Share of Manufacturers (2014-2020)
      • 6.1.3 Northeast Oncology Biosimilars Price (USD/Unit) of Manufacturers (2014-2020)
      • 6.1.4 Northeast Oncology Biosimilars Gross Margin of Manufacturers (2014-2020)
      • 6.1.5 Market Concentration
    • 6.2 Midwest Market Performance for Manufacturers
      • 6.2.1 Midwest Oncology Biosimilars Sales (K Units) and Share of Manufacturers (2014-2020)
      • 6.2.2 Midwest Oncology Biosimilars Revenue (M USD) and Share of Manufacturers (2014-2020)
      • 6.2.3 Midwest Oncology Biosimilars Price (USD/Unit) of Manufacturers (2014-2020)
      • 6.2.4 Midwest Oncology Biosimilars Gross Margin of Manufacturers (2014-2020)
      • 6.2.5 Market Concentration
    • 6.3 South Market Performance for Manufacturers
      • 6.3.1 South Oncology Biosimilars Sales (K Units) and Share of Manufacturers (2014-2020)
      • 6.3.2 South Oncology Biosimilars Revenue (M USD) and Share of Manufacturers (2014-2020)
      • 6.3.3 South Oncology Biosimilars Price (USD/Unit) of Manufacturers (2014-2020)
      • 6.3.4 South Oncology Biosimilars Gross Margin of Manufacturers (2014-2020)
      • 6.3.5 Market Concentration
    • 6.4 West Market Performance for Manufacturers
      • 6.4.1 West Oncology Biosimilars Sales (K Units) and Share of Manufacturers (2014-2020)
      • 6.4.2 West Oncology Biosimilars Revenue (M USD) and Share of Manufacturers (2014-2020)
      • 6.4.3 West Oncology Biosimilars Price (USD/Unit) of Manufacturers (2014-2020)
      • 6.4.4 West Oncology Biosimilars Gross Margin of Manufacturers (2014-2020)
      • 6.4.5 Market Concentration

    7 USA Oncology Biosimilars Market Performance (Sales Point)

    • 7.1 USA Oncology Biosimilars Sales (K Units) and Market Share by Regions (2014-2020)
    • 7.2 USA Oncology Biosimilars Revenue (M USD) and Market Share by Regions (2014-2020)
    • 7.3 USA Oncology Biosimilars Price (USD/Unit) by Regions (2014-2020)
    • 7.4 USA Oncology Biosimilars Gross Margin by Regions (2014-2020)

    8 Development Trend for Regions (Sales Point)

    • 8.1 USA Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate(2014-2020)
    • 8.2 Northeast Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate(2014-2020)
    • 8.3 Midwest Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate(2014-2020)
    • 8.4 South Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate(2014-2020)
    • 8.5 West Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate(2014-2020)

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Retail Pharmacies Industry
    • 11.2 Hospital Pharmacies Industry
    • 11.3 Online Pharmacies Industry

    12 Market Forecast 2021-2026

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
      • 12.1.1 USA Oncology Biosimilars Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
      • 12.1.2 USA Oncology Biosimilars Sales (K Units) and Growth Rate 2021-2026
      • 12.1.3 Northeast Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.4 Midwest Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.5 South Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.6 West Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.7 Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.8 Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.9 Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.10 Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2021-2026
      • 12.3.1 Overall Market Performance
      • 12.3.2 G-CSF Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.3.3 Hematopoietic Agents Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.3.4 Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.4 Sales by Application 2021-2026
      • 12.4.1 Overall Market Performance
      • 12.4.2 Retail Pharmacies Sales and and Growth Rate 2021-2026
      • 12.4.3 Hospital Pharmacies Sales and and Growth Rate 2021-2026
      • 12.4.4 Online Pharmacies Sales and and Growth Rate 2021-2026
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 USA Oncology Biosimilars Price (USD/Unit) Trend 2021-2026
      • 12.5.2 USA Oncology Biosimilars Gross Profit Trend 2021-2026

    13 Conclusion

    In this report, our team research the USA Oncology Biosimilars market by type, application, region and manufacturer (2014-2020) and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

    Geographically, this report split USA into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Oncology Biosimilars for these regions, from 2014 to 2026 (forecast), including
    Northeast
    Midwest
    South
    West

    USA Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Celltrion Inc.
    Pfizer Inc.
    Biocon
    BIOCAD
    Apotex Inc.
    Dr. Reddy's Laboratories Ltd.
    Sandoz International GmbH
    Intas Pharmaceuticals Ltd.
    STADA Arzneimittel AG
    Teva Pharmaceutical Industries Ltd.

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    G-CSF
    Hematopoietic Agents
    Monoclonal Antibodies

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Oncology Biosimilars for each application, including
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

    If you have any special requirements, please let us know and we will offer you the report as you want.
    Buy now